ArticleClinicoEconomics and outcomes research : CEOR2026
Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.
Jennifer E Vaughn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.